Monopar TherapeuticsMNPR
13F holders, Q4 2024 (December 31)18holders +12
11new positions
0sold out
1famous investor
$22.16avg. 13F price*
At the end of Q4 2024, 18 institutions reported holding Monopar Therapeutics Inc. (MNPR) in their 13F filings, up 12 from Q3 2024. 11 opened new positions and 0 sold out. The largest holders were Janus Henderson Group PLC ($23.4M), Adage Capital Partners Gp, L.L.C. ($13.2M) and Ra Capital Management, L.P. ($11.2M). One famous investor held it Steve Cohen (0.0% of Point72 Asset Management's portfolio).
- Company
- Monopar Therapeutics Inc.
- CUSIP
- 61023L207
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 11 | $56.1M |
| Exits | 0 | $0 |
All 13F filers, Q3 2024 → Q4 2024: 2,562,738 shares bought and 250 shares sold, net +2,562,488 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 18 holders
| Janus Henderson Group PLC | 0.01% | New | 1,046,899 | $23.4M |
| Adage Capital Partners Gp, L.L.C. | 0.02% | New | 599,195 | $13.2M |
| Ra Capital Management, L.P. | 0.15% | New | 511,207 | $11.2M |
| Point72 Asset Management | 0.01% | New | 167,892 | $3.7M |
| ADAR1 Capital Management, LLC | 0.61% | New | 130,037 | $2.9M |
| Vanguard Group Inc. | 0.00% | New | 56,509 | $1.2M |
| Geode Capital Management, LLC | 0.00% | Add +174.4% | 38,596 | $849K |
| BlackRock, Inc. | 0.00% | New | 8,101 | $178K |
| UBS Group AG | 0.00% | Add +1154.5% | 6,423 | $141K |
| Ikarian Capital, LLC | 0.04% | New | 5,908 | $130K |
| Morgan Stanley | 0.00% | New | 3,801 | $84K |
| JPMorgan Chase & Co. | 0.00% | New | 2,037 | $45K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 696 | $15K |
| NewEdge Advisors, LLC | 0.00% | No change | 600 | $13K |
| Wells Fargo & Company | 0.00% | Reduce -50.0% | 250 | $6K |
| SBI Securities Co., Ltd. | 0.00% | — | 100 | $2K |
| Bank of America Corp. | 0.00% | Add +115.4% | 28 | $616 |
| Federation des caisses Desjardins du Quebec | 0.00% | No change | 16 | $352 |
"% of holder's portfolio" is MNPR's weight in each manager's 13F, not the share of Monopar Therapeutics Inc. the manager owns.